Innovus Pharma to Request Regulatory Guidance for Filing for Its FlutiCare Product in Europe for the Treatment of Allergic Rhinitis
Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQBVenture Market:INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that it will seek regulatory guidance from the United Kingdom's MHRA as a Reference Member State in Europe before submitting its European application for its FlutiCare™ (50mcg fluticasone propionate) 60 and 120 sprays/bottle.
View full press release